iTeos Therapeutics, Inc.
ITOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $310,843 | $391,611 | $694,331 | $1,638,045 |
| - Cash | $142,131 | $251,177 | $284,803 | $848,537 |
| + Debt | $5,096 | $6,058 | $4,673 | $5,341 |
| Enterprise Value | $173,808 | $146,492 | $414,201 | $794,849 |
| Revenue | $35,000 | $12,595 | $267,630 | $344,775 |
| % Growth | 177.9% | -95.3% | -22.4% | – |
| Gross Profit | $33,762 | $11,697 | $266,817 | $344,160 |
| % Margin | 96.5% | 92.9% | 99.7% | 99.8% |
| EBITDA | -$121,823 | -$111,659 | $148,377 | $257,079 |
| % Margin | -348.1% | -886.5% | 55.4% | 74.6% |
| Net Income | -$134,414 | -$112,642 | $96,652 | $214,521 |
| % Margin | -384% | -894.3% | 36.1% | 62.2% |
| EPS Diluted | -3.32 | -3.15 | 2.56 | 5.68 |
| % Growth | -5.4% | -223% | -54.9% | – |
| Operating Cash Flow | -$98,181 | -$103,756 | -$111,193 | $513,140 |
| Capital Expenditures | -$1,633 | -$2,966 | -$938 | -$1,181 |
| Free Cash Flow | -$99,814 | -$106,722 | -$112,131 | $511,959 |